Neurotech Pharmaceuticals has made history by treating a patient outside of a clinical trial with its new therapy, Encelto, for idiopathic macular telangiectasia type 2 (MacTel). The US FDA approved Encelto earlier this year as the first treatment for the disease. A one-time surgical procedure was performed to implant a capsule that delivers therapeutic proteins over time, designed to slow photoreceptor loss and maintain visual function in patients with MacTel. This milestone marks a significant advancement in treating the progressive retinal disease.
Source: https://conexiant.com/ophthalmology/articles/first-mactel-patient-receives-encelto-treatment